What is the Descartes-30 Clinical Trial?
This Phase I/II study is evaluating the safety and feasibility of an investigational cell therapy called Descartes-30 in eligible patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). ARDS typically occurs in people who are already critically ill or who have significant injuries. Patients with ARDS due to COVID-19 who meet eligibility criteria will receive priority enrollment and treatment.
Am I eligible?
A patient is eligible if he/she is 18 years and older and has:
- a diagnosis of moderate-to-severe ARDS as per Berlin Criteria;
- been diagnosed with ARDS for less than 96 hours;
- informed consent from participant or health care proxy
Patients who are currently on ECMO or had recent treatment with Pulmozyme® (dornase alfa) after diagnosis of ARDS will be excluded.
Additional inclusion and exclusion criteria are available on ClinicalTrials.gov.
What To Expect?
Upon intravenous administration, Descartes-30 cells are intended to home to the lungs of patients with ARDS. Once they arrive, the cells secrete a combination of enzymes to eliminate Neutrophil Extracellular Traps (“NETs”), which are inflammatory webs of DNA and toxic proteins that are thought to contribute to ARDS.
How will I receive Descartes-30?
Descartes-30 will be infused into your bloodstream daily for a total of three days. These cells are prepared and shipped to your hospital in advance.